Oral Biologics & Biosimilars Market Report 2025-2034: Industry Overview, Trends, And Forecast Analysis

The Oral Biologics & Biosimilars Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Current Oral Biologics & Biosimilars Market Size and Its Estimated Growth Rate?
The market size for oral biologics and biosimilars has undergone tremendous growth in the past few years. It is projected to rise from $7.04 billion in 2024 to $8.69 billion in 2025, boasting a compound annual growth rate (CAGR) of 23.5%. The noteworthy growth in the historical period is the result of increased partnerships and collaborations among market players for superior insights, a rising necessity for immunology, amplified demand driven by cost-effective production processes, an aging population, initiatives from the government, and the capacity to dictate high prices.

In the upcoming years, the market size for oral biologics and biosimilars is anticipated to witness tremendous growth, with an estimated value of $19.13 billion in 2029 and a compound annual growth rate (CAGR) of 21.8%. This projected surge during the forecast period can be credited to several factors like intense research and development pursuits in the area of oral biologics, a preference for tablets over injections, adoption of unhealthy lifestyles, technological progression, convenience of oral biologics use, improved access to healthcare, biologics reimbursement, a surge in biosimilars, and an increasing occurrence of chronic diseases. Major market trends for the forecast period involve investment in the oral biologics market for potentially high profit margins, transition towards biologics due to their rising innovation rate, and the creation of microneedle injector-based drugs to boost bioavailability and mitigate side effects of the subcutaneous route.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6830

How Are Emerging Segments Shaping the Oral Biologics & Biosimilars Market Landscape?
The oral biologics & biosimilars market covered in this report is segmented -

1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors, Immunostimulants, GPCR Modulators, Other Tharpies
2) By Disease: Diabetes, Arthritis and Crohn's Disease, Cancer, Infectious Disease, Other Autoimmune Disease, Other Diseases
3) By Molecule Type: Vaccines, Proteins and Peptides, Monoclonal Antibodies, Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Lymphocyte Modulators: T-Cell Modulators, B-Cell Modulators, Sphingosine-1-Phosphate Receptor Modulators
2) By Interleukin Inhibitors: IL-1 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, IL-23 Inhibitors
3) By Tumor Necrosis Factor-Alpha Inhibitors: TNF-a Blockers, Monoclonal Antibodies Targeting TNF-a
4) By Immunostimulants: Cytokines, Immune Checkpoint Inhibitors, Adjuvants
5) By GPCR Modulators: Agonists, Antagonists, Biased Ligands
6) By Other Therapies: Cell-Based Therapies, Gene Therapies, Combination Therapies

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp

Which Growth Factors Are Influencing Oral Biologics & Biosimilars Market Expansion?
An increase in chronic conditions such as arthritis, asthma, and cancer is anticipated to drive the growth of the oral biologics and biosimilar market. Factors such as extended work periods, limited physical exercise, and unhealthy dietary practices contribute to the development of these chronic illnesses, and biologics are progressively being employed for their treatment. Biologics aid in bolstering the immune system's attack on cancerous cells, supporting the body's natural defense mechanisms in eliminating the pathogenic cells. A report by a US-based intergovernmental organisation mentioned in a United Nations article predicts that by 2030, chronic diseases will be responsible for approximately 70% of all deaths globally. The expected proportion of global deaths due to chronic diseases is near 60%. Thus, the escalating prevalence of chronic diseases is stimulating the growth of the biologics and biosimilar market.

Who Are the Dominant Players Across Different Oral Biologics & Biosimilars Market Segments?
Major companies operating in the oral biologics & biosimilars market include Merck & Co. Inc., GlaxoSmithKline, Novo Nordisk, ALK-Abelló, Aimmune Therapeutics Inc., VIVUS Inc, Materia Medica Holding, VECTOR-MEDICA, Henlius, Innovent Biologics, Bio-Thera, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Shanghai Fosun Pharmaceuticals, Biocon, Dr.Reddy's, Mylan, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, BiosanaPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Sanofi, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Roche, Rani Therapeutics, Eli Lilly and Company, Emisphere Technologies Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Pfizer Inc., Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Altis Biologics, Cipla Medpro South Africa, Genzyme

What Oral Biologics & Biosimilars Market Trends Are Gaining Traction Across Different Segments?
The emergence of new insulin biosimilars is a significant trend observed in the oral biologics and biosimilar market. Key players in this market are strategically investing in the development of a biosimilar version of insulin to expand their market presence. An example of this is Amgen's launch of Amjevita, a US-based biotechnology company, in January 2023. This product, a biosimilar to Humira, represents advancements in the creation of insulin biosimilars. Amgen's goal is to make vital treatments more affordable and widely available. Amjevita offers a cost-effective alternative for conditions such as arthritis and Crohn's disease, while insulin biosimilars make diabetes treatments more affordable and accessible. These efforts stimulate competition and foster innovation in the biologics sector. The company's core commitment revolves around the discovery, development, manufacture, and delivery of innovative, human-based therapeutics.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report

Which Geographic Regions Are Expected to Dominate the Oral Biologics & Biosimilars Market in the Coming Years?
North America was the largest region in the oral biologics and biosimilar drugs market in 2024. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the oral biologics & biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Oral Biologics & Biosimilars Market?
2. What is the CAGR expected in the Oral Biologics & Biosimilars Market?
3. What Are the Key Innovations Transforming the Oral Biologics & Biosimilars Industry?
4. Which Region Is Leading the Oral Biologics & Biosimilars Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.